

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

TARASSENKO et al. Atty. Ref.: 117-537

Serial No. 10/528,365 TC/A.U.: 3736

Filed: July 19, 2005 Examiner: NAQI, Sharick

For: TELEMEDICINE SYSTEM

\* \* \* \* \* \* \* \* \* \* \*

November 7, 2007

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

## INFORMATION DISCLOSURE STATEMENT

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicants have checked the appropriate boxes below. 11/88/2007 SZEWDIE1 00000035 10528365

802 FC:1806 180.00 OP

1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement

under 37 C.F.R. § 1.97(e) or fee is required. In the event, a first Office Action has been mailed prior to filing of the present Information Disclosure Statement, the Office is requested to treat the present paper s a submission under 37 C.F.R. § 1.97(c) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p). The present paper is submitted in duplicate for this purpose.

in duplica	te fo	or this purpose.
2.	$\boxtimes$	This Information Disclosure Statement is being filed more than three months
after the U	J.S.	filing date AND after the mailing date of the first Office Action on the merits, but
before the mailing date of a Final Rejection or Notice of Allowance.		
	a.	☐ I hereby state that each item of information contained in this Information
		Disclosure Statement was cited in a communication from a foreign patent office
		in a counterpart foreign application not more than three months prior to the filing
		of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
	b.	☐ I hereby state that no item of information in this Information Disclosure
		Statement was cited in a communication from a foreign patent office in a
		counterpart foreign application, and, to my knowledge after making reasonable
		inquiry, no item of information contained in this Information Disclosure
		Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more
		than three months prior to the filing of this Information Disclosure Statement. 37
		C.F.R. § 1.97(e)(2).
	c.	Attached is our Check in the amount of \$180.00 in payment of the fee under
		37 C.F.R. § 1.17(p).
3.		This Information Disclosure Statement is being filed more than three months
after the U	J.S.	filing date and after the mailing date of a Final Rejection or Notice of Allowance,
but before	pay	ment of the Issue Fee. It is hereby requested that the Information Disclosure
Statement	be o	considered. Attached is our Check No. in the amount of \$ in payment of the fee
under 37 (	C.F.1	R. § 1.17(i).
	a.	☐ I hereby state that each item of information contained in this Information
		Disclosure Statement was cited in a communication from a foreign patent office
		in a counterpart foreign application not more than three months prior to the filing
		of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
	b.	☐ I hereby state that no item of information in this Information Disclosure
		Statement was cited in a communication from a foreign patent office in a
		counterpart foreign application, and, to my knowledge after making reasonable

inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2). 4. Relevance of the non-English language document(s) is discussed in the present specification. 5. The document(s) was/were cited in a corresponding application. An English language version of the foreign search report is attached for the Examiner's information and provides a statement of relevance for non-English-language documents (if any). 6. A concise explanation of the relevance of the non-English language document(s) appears below: 7. The Examiner's attention is directed to co-pending U.S. Patent Application No., filed, (copy attached) which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

these documents are not attached. 37 C.F.R. § 1.98(d).

No., filed which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of

8.  $\square$  Copies of the documents were cited by or submitted to the Office in Application

TARASSENKO et al. Serial No. 10/528,365

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 14-1140 referencing docket number 117-537.

Respectfully submitted,

NIXON & VANDERHYE P.C.

Michael J. Shea Reg. No. 34,725

MJS:dbp

901 North Glebe Road, 11th Floor

Arlington, VA 22203-1808

Telephone: (703) 816-4000 Facsimile: (703) 816-4100